Pay in 4 interest-free payments of $6.83 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
Patient enrollment began in January 2014 and ended when the target sample size was reached in September 2014
7,8 Though safety and efficacy data is not yet available, an upcoming phase 1 study looking at ivermectin in patients with triple negative breast cancer (in combination with balstilimab, a chemotherapeutic agent) plans to evaluate dosing at 30, 45, or 60mg daily on days 1-2, 8-10, and 15-17 in a 21 day cycle until disease progression or intolerance
There are no standardized guidelines
We focus on developing new products, exploring new markets, and strive to master various advanced skills to strengthen self-improvement
Desde entonces, se ha estudiado en animales para evaluar su potencial en la reparacin de tejidos, la reduccin de la inflamacin y la aceleracin de la cicatrizacin
Product Information SKUBPC157-5MG Strength5mg CAS137525-51-0 Molecular Weight1419.5 g/mol FormulaC62H98N16O22 CategoryRecovery Research UseResearch Use Only Label / Documentation Label Preview COA (Batch) Third-Party TestedYes Purity99%+ Made in USAYes Research Use OnlyYes For laboratory research use only
US$ 23.48
US$ 23.64
US$ 28.42
US$ 28.69
